Replication-Competent, Tumor-Specific Immuno-Gene Vectors Allow for Exchange of Transgenes and Lead to Viral Persistence Following IV Administration [0.03%]
具备复制能力和肿瘤特异性的免疫基因载体可在静脉给药后进行转基因交换并导致病毒持久存在
Lee S Rosen,Christian Ottensmeier,Maria Hawkins et al.
Lee S Rosen et al.
Introduction: Enadenotucirev (EnAd) and successor transgene-armed Tumor-Specific Immuno-Gene (T-SIGn) vectors are replication-competent, blood-stable viral vectors that traffic to tumor sites following intravenous (IV) ad...
Khanh Toan Nguyen,Thi Huong Pham,Van Lam Ngo et al.
Khanh Toan Nguyen et al.
Introduction: This study aims to document patient characteristics, treatment modalities, and survival outcomes of patients with lung cancer in Vietnam from 2018 to 2024. ...
Phase 2 Study of Monotherapy with Pembrolizumab for Advanced Adrenocortical Carcinoma [0.03%]
帕博利珠单抗治疗晚期肾上腺癌的Ⅱ期研究
Brenda Chahla,Bettzy Stephen,Juhee Song et al.
Brenda Chahla et al.
Introduction: Adrenocortical carcinoma (ACC) is a rare cancer with suboptimal response to chemotherapy. The role of immunotherapy in ACC management is evolving. ...
Characterizing Inquiries About Novel Cancer Therapies: Findings from the National Cancer Institute's Cancer Information Service [0.03%]
关于新型癌症疗法咨询的特点研究——美国国家癌症研究所癌症信息部的研究成果分析
Robin C Vanderpool,Laura Dwyer,Diane Ng et al.
Robin C Vanderpool et al.
Exceptional Response to Immunotherapy-based Treatment in Compound EGFR-Mutated Oligometastatic Pulmonary Sarcomatoid Carcinoma: A Case Report [0.03%]
免疫治疗联合治疗复合型EGFR突变寡转移肺肉瘤样癌的应答：一例报告
Ayushi Gianchandani,Darshana Desai,Janani Sambath et al.
Ayushi Gianchandani et al.
Pulmonary sarcomatoid carcinoma (PSC) is a rare and aggressive subtype of non-small cell lung cancer (NSCLC) with limited treatment options and poor prognosis. EGFR mutations generally respond to tyrosine kinase inhibitors (TKIs)-based targ...
Immunotherapy and Targeted Therapies in Sarcoma: Proposed Synergy with Combination Treatment [0.03%]
免疫疗法和靶向疗法在肉瘤治疗中的协同作用：联合治疗的建议与展望
Aleksandra Watson,Gina D&#x;Amato,Emily Jonczak et al.
Aleksandra Watson et al.
The combination of targeted therapies and immunotherapies for advanced and metastatic sarcomas has been proposed owing to the enhanced effect of antiangiogenic therapies on the tumor microenvironment. We found eight studies published to dat...
Circulating Tumor DNA as a Prognostic Biomarker for Selecting Participants to Early Phase Clinical Trials [0.03%]
循环肿瘤DNA作为早期临床试验受试者选择的预后生物标志物
Sammy Shaya,Okezie Uche-Ikonne,Bedirhan Kilerci et al.
Sammy Shaya et al.
Introduction: Patients with advanced solid tumors may be considered for early phase clinical trials investigating the safety, tolerability, and dosing of experimental therapies. Optimizing participant selection is critica...
More Than Medicine: The Hope, Hurdles, and Hidden Costs of IgG Therapy [0.03%]
超越药物：免疫球蛋白治疗的希望、障碍和隐性成本
Christopher Boldt,Huifang Lu
Christopher Boldt
Prevalence of Molecular Mutations in Non-Small Cell Lung Cancer and Current Treatment Approaches in the MENA Region: Systematic Review and Expert Opinion [0.03%]
中东和北非地区非小细胞肺癌分子突变的流行率及当前治疗方法：系统评价与专家意见
AbdulAziz AlJassim,Aladdin Kanbour,Fathi Azribi et al.
AbdulAziz AlJassim et al.
Over the past decade, the discovery of immunotherapy and targeted therapy has set new standards for the management of advanced non-small cell lung cancer (NSCLC). This study aims to investigate the prevalence of ALK, EGFR, KRAS, ROS1, MET, ...